)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
BridgeBio
BridgeBio (BBIO) investor relations material
BridgeBio Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary24 Feb, 2026
Executive summary
Achieved strong commercial execution with Attruby, delivering significant revenue growth and market share gains in ATTR cardiomyopathy, and advanced three late-stage pipeline assets with positive phase III results: encaleret (ADH1), BBP-418 (LGMD2I), and infigratinib (achondroplasia), with multiple NDA submissions planned for 2026.
Achieved $154.2 million in Q4 2025 net revenues and $502.1 million for the full year, driven by strong commercial performance of Attruby and pipeline progress.
Transitioning from a cash-consuming to a cash-generating business, with expectations of over $600 million in profit by 2028, driven by four post-phase III assets.
Maintains robust financial position with over $1 billion in capital and a fully financed base business, supporting upcoming regulatory launches and lifecycle expansion.
Attruby prescriptions reached 7,804 by 1,856 prescribers as of February 2026, reflecting rapid market adoption.
Financial highlights
Q4 2025 total/net revenues reached $154.2 million, up from $5.9 million in Q4 2024, driven by $146 million in Attruby net product revenue.
Full year 2025 revenues were $502.1 million, up from $221.9 million in 2024, with Attruby contributing $362.4 million.
Operating costs and expenses for 2025 were $1.03 billion, up from $814.9 million in 2024, mainly due to increased SG&A for commercial launches.
Net loss attributable to common stockholders was $724.9 million for 2025, compared to $535.8 million in 2024.
Ended 2025 with $587.5 million in cash, equivalents, and marketable securities; issued $632.5 million in convertible notes in January 2026.
Outlook and guidance
NDA submissions for BBP-418 and encaleret planned for 1H 2026, with U.S. launches anticipated in late 2026/early 2027.
NDA for infigratinib in achondroplasia expected in 2H 2026, with launch planned for early to mid-2027.
Cash burn expected to hold steady through 2026, then decline as Attruby revenue increases and new launches approach.
Anticipates cash generation beginning in late 2027, with significant EBITDA and profit growth by 2028.
Company expects to achieve six approved products as its first decade concludes.
How does Attruby's market differentiation sustain growth?
Future launch strategy for BBP-418, encaleret, infigratinib
Capital efficiency strategy with 2033 convertible notes
How will diversified assets drive 2028 profit?
Basis for Attruby's post-TAF IP confidence?
New asset global launch footprint plans?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BridgeBio earnings date
TD Cowen 46th Annual Health Care Conference2 Mar, 2026
BridgeBio
Next BridgeBio earnings date
TD Cowen 46th Annual Health Care Conference2 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company's lead candidates for the treatment of Fabry disease comprise a pipeline of recombinant enzyme-replacement therapies comprising elaprase and lysosomal-phospholipid-glycoprotein (PLG) analogs. It focuses on developing therapeutics for treating Fabry disease, a rare genetic disorder characterized by progressive loss of kidney function and the buildup of fatty substances that damage blood vessels and organs. BridgeBio Pharma, Inc.i s based in Waltham, Massachusetts.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage